Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Mar;63(3):292-9.
doi: 10.1111/j.1365-2125.2006.02757.x. Epub 2006 Aug 30.

Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia

Samir Gupta  1 , Juif Jen, Karen Kolz, David Cutler
Affiliations
Randomized Controlled Trial

Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia

Samir Gupta et al. Br J Clin Pharmacol. 2007 Mar.

Abstract

Aims: To assess the dose selection using population pharmacokinetics of Pegylated Intron-alpha2b (PEG-Intron) in patients with chronic myelogenous leukaemia (CML).

Methods: PEG-Intron 3-6 microg kg(-1) was administered subcutaneously once a week and blood samples were collected up to 48 weeks of treatment. A total of 624 samples collected from 137 patients were included in the analysis. Nonlinear mixed-effects modelling was used to analyse the sparsely sampled concentration data from a clinical efficacy trial. Covariates in the analysis included weight, sex, age, race, serum creatinine and estimated creatinine clearance (CLcr).

Results: The apparent clearance of PEG-Intron decreased after repeated dosing. The clearance at treatment week 4 was 42.3 l day(-1) (patients with CLcr 120 ml min(-1)) with interpatient variability 30%. At treatment week 48, the clearance value was reduced to 69% of its week 4 value. CLcr, a composite variable calculated from body weight, sex, age and serum creatinine, had a small but statistically significant influence on the clearance of PEG-Intron. The clearance of PEG-Intron in patients with CML was 40% higher than that of hepatitis C virus-infected patients.

Conclusion: The dose of PEG-Intron 6.0 microg kg(-1) week(-1) appeared appropriate in the treatment of patients with CML.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plots of PEG-Intron immunoassay concentration data (pg ml−1) vs. elapsed time from last dose by treatment week. The broken line is the fitted line generated using population mean parameters
Figure 3
Figure 3
Individual T50 estimates vs. covariates and some clinical and demographic variables
Figure 4
Figure 4
Mean PEG-Intron apparent clearance relative to duration of treatment. The solid line is for the current chronic myelogenous leukaemia trial and the three broken lines are for previous chronic hepatitis C trial [9, 10]. The smooth lines (solid and broken) were obtained using local linear regression (‘loess’ function in S-plus). 6.0 mcg/kg (——–), 0.5 mcg/kg (—), 1.0 mcg/kg (—), 1.5 mcg/kg (—)
Figure 2
Figure 2
Individual CL0 estimates vs. covariates and some demographic and clinical variables
See this image and copyright information in PMC

References

    1. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia. Biol Ther Ann Intern Med. 1999;131:207. - PubMed
    1. Kantarjian HM, O’Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood. 1996;87:3069–81. - PubMed
    1. Talpaz M, Kantarjian H, Kurzrock R. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med. 1991;114:532. - PubMed
    1. Kantarjian HM, Smith TL, O’Brien S. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med. 1995;122:254–61. - PubMed
    1. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S and the Hepatitis C Study Group. PEG-interferon alfa-2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Clin Pharmacol Ther. 2000;68:556–67. - PubMed

Publication types